Ionizable Lipid Nanoparticles for Nucleic Acid Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current liposomal delivery systems face challenges in stability and efficient release of therapeutic agents to targeted cells and tissues, with cationic lipids being toxic and neutral liposomes having low encapsulation efficiency.
Innovation Solution
Development of novel lipids with cleavable linker groups that modulate surface charge, allowing for efficient encapsulation and release of therapeutic agents by altering the liposomal composition's charge through chemical or enzymatic cleavage.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If cationic lipids are used to construct liposomal vehicles, then encapsulation efficiency of negatively charged nucleic acids is improved, but toxicity increases and pharmacokinetic properties deteriorate
Solution Approach 1:
The patent employs ionizable lipids that dynamically change their surface charge properties in response to environmental pH changes. The lipids transition from cationic at physiological pH (for efficient nucleic acid encapsulation) to neutral or anionic at intracellular pH (for reduced toxicity and enhanced release), resolving the contradiction between encapsulation efficiency and toxicity
Solution Approach 2:
The invention modifies the charge parameter of the liposomal surface by using pH-responsive ionizable lipids. The surface charge transitions from positive to neutral/negative based on pH conditions, allowing the system to optimize both encapsulation efficiency (at higher pH) and reduce toxicity (at lower pH) without compromise
2Reliability
If cationic lipids are used to construct liposomal vehicles, then encapsulation efficiency is improved, but pharmacokinetic properties and distribution to targeted tissues are worsened due to rapid clearance
Solution Approach 1:
The ionizable lipids provide dynamic charge adjustment where the liposomal surface appears cationic in the circulation environment (facilitating nucleic acid loading) but transitions to neutral/anionic in the intracellular environment (reducing clearance and extending circulation time), thereby resolving the contradiction between encapsulation efficiency and pharmacokinetic properties
3Object-affected harmful factors
If neutral lipids are used to construct liposomal vehicles, then toxicity is reduced, but encapsulation efficiency of nucleic acids deteriorates
Solution Approach 1:
The patent uses ionizable lipids that are neutral at physiological pH (reducing toxicity) but become cationic at intracellular pH (enhancing nucleic acid encapsulation and release), thereby resolving the contradiction between toxicity and encapsulation efficiency through pH-triggered charge transformation
4Ease of operation
If conventional liposomal vehicles are used, then delivery to targeted cells is achieved, but stable release of encapsulated contents to targeted cells and tissues remains problematic
Solution Approach 1:
The ionizable lipids provide pH-triggered dynamic behavior where the liposomal membrane remains stable at physiological pH but undergoes charge transformation at intracellular pH, facilitating controlled release of encapsulated contents while maintaining delivery stability, thereby resolving the contradiction between delivery capability and release stability
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances encapsulation efficiency and stability of therapeutic agents, improving their delivery to target cells while minimizing toxicity and improving pharmacokinetic properties.
Implementation Method 1
novel lipids with cleavable linker groups that modulate surface charge, allowing for efficient encapsulation and release of therapeutic agents by altering the liposomal composition's charge through chemical or enzymatic cleavage
Data Source
AI summary
Disclosed herein are novel lipids and liposomal compositions prepared using such compounds and related methods of neutralizing or otherwise modifying such liposomal compositions. The lipids described herein are useful for example, as liposomal vehicles to facilitate the delivery of encapsulated polynucleotides to target cells and the subsequent transfection of such target cells. In certain embodiments, one or more of the compounds that comprise the liposomal delivery vehicle may be neutralized or further modified such that the properties of the liposomal delivery vehicle are modified.